Home›Stock Screener›Samrat Pharmachem

Samrat Pharmachem Share Price Today | Stock Price & Samrat Pharmachem Share Screener

SAMRATPH Pharmaceuticals
Live Share Price BSE
₹240.40
▲ 7.55 (3.24%)
2026-10-05 00:00:00

As of October 5, 2026, the live Samrat Pharmachem share price (BSE: SAMRATPH) is ₹240.40, up 3.24% from the previous close, with shares trading between ₹231.10 and ₹244.00 in today's trading session, and a 52-week range of ₹194.95–₹296.70. Check Samrat Pharmachem yearly highs lows for the annual price range and momentum. Use the Samrat Pharmachem stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Samrat Pharmachem opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹295 and net income of ₹-2, an operating margin of -1.0% and a profit margin of -0.7%.

Samrat Pharmachem Market Cap ₹73.80 Cr.
SAMRATPH P/E Ratio (TTM) -32.61
Samrat Pharmachem P/B Ratio 1.06
EPS (TTM) ₹-10.72
Dividend Yield -
Debt to Equity 0.15
SAMRATPH 52 Week High ₹296.70
Samrat Pharmachem 52 Week Low ₹194.95
Operating Margin -1.00%
Profit Margin -0.68%
SAMRATPH Revenue (TTM) ₹295.00
EBITDA -
Net Income ₹-2.00
Total Assets ₹124.00
Total Equity ₹68.00

Samrat Pharmachem Share Price Chart

Track the current stock price of Samrat Pharmachem with an interactive chart. Analyse SAMRATPH share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Samrat Pharmachem stock quote in one place.

The quote of ₹240.40 sits between the 52-week low of ₹194.95 and the 52-week high of ₹296.70, and the latest session moved 3.24% from the previous close.

Samrat Pharmachem Company Profile - Fundamental Screener

Screen Samrat Pharmachem company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for SAMRATPH shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE103E01016.

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals
Sub-Sector Pharmaceuticals
Segment E

Identifiers and Leadership

ISIN INE103E01016

Samrat Pharmachem Balance Sheet Screener

Screen SAMRATPH balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹124, up from ₹122 in 2025.

Latest statistics put total assets at ₹124 and shareholder funds at ₹68, with a leverage ratio of 0.15.

Item 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017

Assets

Total Assets 124 122 122 117 85 57 58 40 41 36
Current Assets 104 103 103 99 71 47 50 33 33 28
Fixed Assets 12 11 11 11 10 9 7 7 7 7

Liabilities

Total Liabilities 0 0 0 0 0 0 0 0 0 0
Current Liabilities 0 0 0 0 1 0 0 1 1 2
Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity 68 72 65 63 47 30 24 20 19 15
Share Capital 3 3 3 3 3 3 3 3 3 3
Reserves & Surplus 65 69 62 60 44 27 21 17 15 12

Samrat Pharmachem Income Statement Screener - Profit & Revenue Analysis

Screen Samrat Pharmachem income statement and profit fundamentals. Analyze SAMRATPH quarterly results. Samrat Pharmachem reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For None-None, revenue was ₹295 and net profit was ₹-2, equal to earnings per unit of ₹-7.10, at an operating margin of -1%.

In that period expenses were ₹295, interest cost ₹1 and tax ₹0. The next period listed, 2026-March, shows revenue of ₹291 and net profit of ₹-3.

Item None-None 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March 2016-March 2015-March

Revenue and Expenses

Revenue 295 291 287 283 311 222 180 138 112 93 71 62 48
Expenses 295 292 276 279 287 198 170 131 108 87 67 61 46

Operating Costs and Margins

EBITDA 0 -1 11 4 24 25 9 7 4 6 4 1 2
Operating Profit % -1.00% -1.00% 4.00% 1.00% 8.00% 11.00% 5.00% 5.00% 3.00% 6.00% 5.00% 2.00% 2.00%
Depreciation 1 1 1 1 1 1 1 0 0 0 0 0 0
Interest 1 1 1 1 1 1 1 1 1 1 1 1 1

Profit and Earnings

Profit Before Tax -2 -3 10 3 23 24 7 6 2 5 3 0 1
Tax 0 0 3 0 6 6 2 2 1 2 1 0 0
Net Profit -2 -3 7 2 17 17 5 4 2 3 2 0 0
EPS -7.10 -10.72 23.02 7.00 53.83 55.62 17.26 13.71 4.97 10.41 5.68 0.97 1.02

Samrat Pharmachem Cash Flow Screener - Liquidity Fundamentals

Screen SAMRATPH cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities generated ₹9, and net cash flow was an inflow of ₹6.

Over the same period, investing activities used ₹3 and financing activities used ₹1.

Item 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March

Cash from Operations and Investing

Operating Activities 9 -10 9 -9 18 5 -1 2 0 -3
Investing Activities -3 0 0 -3 -1 -3 -2 2 -2 1

Financing and Net Cash

Financing Activities -1 1 -11 10 -2 -2 2 -4 2 1
Net Cash Flow 6 -10 -2 -3 15 0 -1 1 -1 -1

Samrat Pharmachem Shareholding Pattern Screener

See Samrat Pharmachem shareholding pattern with promoter, FII, and DII holdings. Check Samrat Pharmachem promoter holding and ownership changes for SAMRATPH on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Mar, promoters held 49.09%, foreign institutions 3.24%, domestic institutions 0.00% and the public 41.75%, spread across 6,311 shareholders.

The shareholder count was 6,311 in 2026-Mar, compared with 6,330 in 2026-Jun.

Item 2026-Mar 2026-Jun 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar 2024-Jun

Promoter Holding

Promoter Holding 49.09% 49.09% 49.09% 49.09% 49.09% 49.09% 48.64% 48.64%

Institutional Investors

FII Holding 3.24% 3.24% 3.24% 0.00% 3.24% 3.24% 3.24% 3.24%
DII Holding 0.00% 0.00% 0.00% 3.24% 0.00% 0.00% 0.22% 0.22%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 41.75% 41.51% 41.58% 41.64% 41.73% 41.50% 41.69% 40.79%
Other Holding 5.93% 6.16% 6.09% 6.04% 5.95% 6.17% 6.22% 7.11%
Shareholder Count 6,311 6,330 6,785 6,752 6,699 6,488 7,478 7,169

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Samrat Pharmachem. Samrat Pharmachem dividend yield can be compared with peers and other stocks in the market.

The latest dividend recorded was ₹0.00 per unit for 2026-March, a yield of 0.00%, compared with ₹1.00 for 2025-March.

Dividends are listed for 10 periods, with the three most recent payouts at ₹0.00, ₹1.00 and ₹1.00 per unit.

Period Dividend Per Share Dividend Yield
2026-March ₹0.00 0.00%
2025-March ₹1.00 0.51%
2024-March ₹1.00 0.32%
2023-March ₹1.00 0.30%
2022-March ₹1.00 0.28%
2021-March ₹0.00 0.00%
2020-March ₹0.00 0.00%
2019-March ₹0.00 0.00%
2018-March ₹0.00 0.00%
2017-March ₹0.00 0.00%

Samrat Pharmachem Stock Index Membership - Nifty & Sensex

See which indices include Samrat Pharmachem stock. Check SAMRATPH index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

Complete Index List

Samrat Pharmachem is not part of any tracked indices.
Only major market indices are tracked in our system.

Samrat Pharmachem Market Events Screener - Corporate Actions

Get Samrat Pharmachem corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Samrat Pharmachem stock events that may affect SAMRATPH share price, along with derivatives, futures and options activity and sector gainers.

15 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated November 14, 2026, with a record date of November 14, 2026.

It is followed by Annual General Meeting dated September 23, 2026 and Quarterly Result Announcement dated August 14, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-11-14 2026-11-14 Quarterly Result Announcement NA 0.37%
2026-09-23 2026-09-23 Annual General Meeting NA -9.22%
2026-08-14 2026-08-14 Quarterly Result Announcement NA 7.64%
2026-05-30 2026-05-30 Quarterly Result Announcement NA 24.45%
2026-02-13 2026-02-13 Quarterly Result Announcement NA 1.56%
2025-11-14 2025-11-14 Quarterly Result Announcement NA -14.06%
2025-09-25 2025-09-25 Annual General Meeting NA -20.77%
2025-09-18 2025-09-18 Dividend ₹ 1.00 /share -18.51%
2025-08-13 2025-08-13 Quarterly Result Announcement NA 0.67%
2025-05-30 2025-05-30 Quarterly Result Announcement NA 24.89%
2025-02-14 2025-02-14 Quarterly Result Announcement NA -9.48%
2024-11-14 2024-11-14 Quarterly Result Announcement NA -16.31%
2024-09-26 2024-09-26 Annual General Meeting NA 48.09%
2024-09-19 2024-09-19 Dividend ₹ 1.00 /share 76.20%
2023-09-18 2023-09-18 Dividend ₹ 1.00 /share -18.65%

Samrat Pharmachem Competitors Screener - Peer Stocks Comparison

Screen SAMRATPH competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 430,681 35.84 61,674 12.69% 11,565 36.68
Divis Laboratories 243,156 84.36 11,067 13.95% 2,568 51.70
Torrent Pharmaceuticals 179,602 84.01 13,886 20.34% 2,138 41.12
Zydus Life Science 113,017 24.88 27,658 17.64% 5,026 47.64
Cipla 107,890 32.42 29,045 2.24% 3,870 34.78
Laurus Labs 106,609 98.56 6,868 22.01% 890 58.70
Mankind Pharma 103,922 50.48 14,636 14.85% 1,938 61.75
Dr Reddys Laboratories 100,370 31.47 35,059 3.90% 4,158 53.84
Aurobindo Pharma 96,232 25.97 34,145 5.56% 3,503 50.30
Lupin 91,975 16.71 29,039 26.75% 5,356 31.59

Samrat Pharmachem Company Announcements - News & Reports Screener

Screen SAMRATPH latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated September 28, 2026.

The next most recent announcements are dated September 28, 2026 and September 26, 2026.

Date Update Actions
2026-09-28 Board Meeting Intimation for Board Meeting Intimation For Un-Audited Financial Results For The Quarter Ended September 30 2026 -
2026-09-28 Closure of Trading Window -
2026-09-26 Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s -
2026-09-26 Scrutinizers Report -
2026-09-23 Shareholder Meeting / Postal Ballot-Outcome of AGM -
2026-09-02 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-08-27 Book Closure: Sunday September 20 2026 To Tuesday September 22 2026 (Both Days Inclusive) -
2026-08-27 34Th Annual General Meeting Of Samrat Pharmachem Limited To Be Held On Wednesday September 23 2026 -
2026-08-27 Reg. 34 (1) Annual Report. -
2026-08-19 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-08-14 Board Meeting Outcome for Outcome Of The Board Meeting Of The Company Held Today -
2026-07-17 Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s -
2026-07-17 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-06-30 Board Meeting Intimation for Notice Of Board Meeting For Un-Audited Financial Results For The Quarter Ended June 30 2026 -
2026-06-29 Closure of Trading Window -
2026-06-29 Closure of Trading Window -
2026-06-04 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-05-30 Board Meeting Outcome for Outcome Of The Board Meeting -
2026-05-30 Audited Financial Results For The Quarter And Year Ended 31 March 2026 -
2026-05-30 Compliances-Reg.24(A)-Annual Secretarial Compliance -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹240.40, within a 52-week range of ₹194.95 to ₹296.70. The P/E ratio is -32.61 and the P/B ratio is 1.06, with earnings per unit of ₹-10.72. Market capitalisation stands at ₹73.80 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the BSE. Key statistics were last updated on October 6, 2026. This page covers 10 balance sheet periods, 13 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.